FindTrial
Sign In

Lecanemab in Early Alzheimer’s Disease: A Multicenter Case Registry Study

Lecanemab in Early Alzheimer’s Disease: A Multicenter Case Registry Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087134
Enrollment
Unknown
Registered
2024-07-22
Start date
2024-07-22
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Case series (Lecanemab therapy):None

Sponsors

The First Affiliated Hospital of Xi’an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: A. Seventeen tertiary Grade A hospitals in the northwest region, treating early-stage AD patients with Lecanemab; B. Voluntarily participate in this study and sign the informed consent form; C. Age =18 years old.

Exclusion criteria

Exclusion criteria: All early-stage AD patients who have received Lecanemab can participate in this study, and there are no exclusion criteria for this study.

Design outcomes

Primary

MeasureTime frame
adverse reaction;Amyloid associated imaging abnormality, ARIA;—

Secondary

MeasureTime frame
CDR-SB;ADAS-cog;DCS-ADL;MMSE;—

Countries

China

Contacts

Public ContactQu Qiumin

The First Affiliated Hospital of Xi’an Jiaotong University

quqiumin@xjtufh.edu.cn+86 138 9289 8562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026